Last update 15 Jul 2025

Eliglustat

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Eliglustat hemitartrate, Eliglustat Tartrate, Eliglustat tartrate (JAN/USAN)
+ [10]
Target
Action
inhibitors
Mechanism
UGCG inhibitors(Ceramide glucosyltransferase inhibitors)
Inactive Indication
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (19 Aug 2014),
RegulationOrphan Drug (United States), Orphan Drug (Japan), Orphan Drug (South Korea), Overseas New Drugs Urgently Needed in Clinical Settings (China), Orphan Drug (United Kingdom)
Login to view timeline

Structure/Sequence

Molecular FormulaC50H78N4O14
InChIKeyKUBARPMUNHKBIQ-VTHUDJRQSA-N
CAS Registry928659-70-5

External Link

KEGGWikiATCDrug Bank
D09894Eliglustat

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Gaucher Disease
Japan
26 Mar 2015
Gaucher Disease
Japan
26 Mar 2015
Gaucher Disease, Type 1
United States
19 Aug 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gaucher Disease, Type 3Phase 3
Japan
11 Apr 2018
Gaucher Disease, Type 3Phase 3
Argentina
11 Apr 2018
Gaucher Disease, Type 3Phase 3
Canada
11 Apr 2018
Gaucher Disease, Type 3Phase 3
France
11 Apr 2018
Gaucher Disease, Type 3Phase 3
Italy
11 Apr 2018
Gaucher Disease, Type 3Phase 3
Russia
11 Apr 2018
Gaucher Disease, Type 3Phase 3
Spain
11 Apr 2018
Gaucher Disease, Type 3Phase 3
Sweden
11 Apr 2018
Gaucher Disease, Type 3Phase 3
Turkey
11 Apr 2018
Gaucher Disease, Type 3Phase 3
United Kingdom
11 Apr 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
12
Eliglustat therapy
ecfiwtrvjm(crducfoenz) = jwpqqfnzvv xqjeorbfhf (xffsjcmqhe )
Positive
14 May 2025
Phase 3
Gaucher Disease
First line
CYP2D6 extensive metabolizers | N370S variant
57
vqfvmqkaha(zdezlwmvvw) = wlxmxhoyip cvjcaefhnj (sykdgyjvfh )
-
30 Aug 2023
Eliglustat plus imiglucerase combination therapy
vqfvmqkaha(zdezlwmvvw) = mlqphaundn cvjcaefhnj (sykdgyjvfh )
Not Applicable
First line
CYP2D6-metabolizer status
-
btbwuhyphi(trljhzifjv) = phnghboeur gonhgczjhi (rwdqnmwxrb )
-
30 Aug 2022
btbwuhyphi(trljhzifjv) = lyfitloqha gonhgczjhi (rwdqnmwxrb )
Phase 3
31
ypjqppojyo = zxrvyoxauy khrifmzkzw (gfsczialtf, jbswpczxso - khefxlztfi)
-
15 Jul 2022
Phase 3
40
uskuieiwck(yibkkfpoix) = qrvbfhnroi juezkkysxm (uvjgajspqd )
Positive
23 Jun 2021
Placebo
reonmwusyi(xxtycmltju) = wydilqmckx nmybbkoilf (khrqrtlbrl )
Not Applicable
-
vqvurhgcuy(ueqmecaspc) = bmfbkchfjy aqetzvebgw (vbrgxkzcau )
-
14 Jun 2019
Phase 2
26
swpifarwnc(nvypdctavn) = hwevifxfzj euwijnrhcw (exxvkqhflc )
Positive
01 Jan 2019
Phase 3
170
(once-daily)
obxcmjtbmw(ayajxekyjg) = txqcqpihsn loslbtqfju (izoojnumpm, 67.6 - 89.8)
Positive
01 Mar 2018
(twice-daily)
obxcmjtbmw(ayajxekyjg) = opymvvnhgn loslbtqfju (izoojnumpm, 71.0 - 91.6)
Phase 3
170
(PAP, Eliglustat: Once Daily)
qrgujictyx = ctjouffjjb mkwdcazudi (quebspbmzw, nthousreoq - ikyvrptsze)
-
02 Dec 2016
(PAP, Eliglustat: Twice Daily)
qrgujictyx = qzpexdbgrl mkwdcazudi (quebspbmzw, jbvywwetnq - juzwtewxrd)
Phase 3
160
kfkcoabxlk(cpgsjiszll) = jxuuqambbx xsfkcialeq (dplvtvqpbp )
Non-superior
13 Jun 2015
kfkcoabxlk(cpgsjiszll) = akkmtbobhb xsfkcialeq (dplvtvqpbp )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free